SavedAdd your journal

Journals / art / 2018 / Cilt: 33 - Sayı: 2

The Assessment of Serum Endocan Levels in Children With Juvenile Idiopathic Arthritis

Yasin YILMAZ
Rana BERRU DURMUŞ
Başak SARAÇOĞLU
Sezgin ŞAHİN
AMRA ADROVIC YILDIZ
Kenan BARUT
SEVDA ÖZEL YILDIZ
Özgür KASAPÇOPUR
Rukiye EKER ÖMEROĞLU
Journal
art
Pages
168–173
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The high level of serum endocan highlighted the endothelial damage in patients with JIA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the levels of serum endocan in children with juvenile idiopathic arthritis (JIA).
📊
Key Findings & Data:Patients and methods: Sixty-seven children with JIA (30 males, 37 females; mean age 10.4±4.9 years; range 2 to 18 years) and a sex- and agematched healthy control group of 39 children (16 males, 23 females; mean age 9.3±4.1 years; range 1 to 17 years) were recruited.
💡
Conclusion & Impact:Conclusion: The high level of serum endocan highlighted the endothelial damage in patients with JIA.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to evaluate the levels of serum endocan in children with juvenile idiopathic arthritis (JIA). Patients and methods: Sixty-seven children with JIA (30 males, 37 females; mean age 10.4±4.9 years; range 2 to 18 years) and a sex- and agematched healthy control group of 39 children (16 males, 23 females; mean age 9.3±4.1 years; range 1 to 17 years) were recruited. Patients with JIA were divided into two groups as the clinically active JIA group (n=27) and inactive JIA group (n=40). Results: The median serum endocan level in patients with JIA was significantly higher than in the control group (633.75 ng/L vs. 379.76 ng/L, p<0.01). Comparison between patients with active JIA and inactive JIA was not significant in terms of endocan levels (618.70 ng/L vs. 687.36 ng/L, p=0.34). There was a weak negative correlation between Childhood Health Assessment Questionnaire scores of patients with JIA and serum endocan levels. Conclusion: The high level of serum endocan highlighted the endothelial damage in patients with JIA.

🔖

Cite This Article

YILMAZ, Y., DURMUŞ, R. B., SARAÇOĞLU, B., ŞAHİN, S., YILDIZ, A. A., BARUT, K., YILDIZ, S. Ö., KASAPÇOPUR, Ö., ÖMEROĞLU, R. E. (2018). The Assessment of Serum Endocan Levels in Children With Juvenile Idiopathic Arthritis. art, Cilt: 33 - Sayı: 2, 168–173. https://ajindex.com/articles/151921

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Balanescu P, Ladaru A, Balanescu E, Voiosu T, Baicu C, Dan GA. Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study. J Clin Lab Anal 2016;30:368-73.
  2. Icli A, Cure E, Cure MC, Uslu AU, Balta S, Mikhailidis DP, et al. Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology 2016;67:749-55.
  3. Halici I, Palabiyik SS, Guducu-Tufekci F, OzbekBilgin A, Cayir A. Endothelial dysfunction biomarker, endothelial cell-specific molecule-1, and pediatric metabolic syndrome. Pediatr Int 2016;58:1124-9.
  4. Kim KS, Lee YA, Ji HI, Song R, Kim JY, Lee SH, et al. Increased expression of endocan in arthritic synovial tissues: effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes. Mol Med Rep 2015;11:2695-702.
  5. Glowinska-Olszewska B, Bossowski A, Dobrenko E, Hryniewicz A, Konstantynowicz J, Milewski R, et al. Subclinical cardiovascular system changes in obese patients with juvenile idiopathic arthritis. Mediators Inflamm 2013;2013:436702. Rusak M, Radzikowska U, Glowinska-Olszewska B, Dobrenko E, Piotrowska-Jastrzebska J, Dabrowska M, et al. Endothelial progenitor cell levels in juvenile idiopathic arthritis patients: effects of antiinflammatory therapies. Pediatr Rheumatol Online J 2015;13:6. van Zonneveld AJ, de Boer HC, van der Veer EP, Rabelink TJ. Inflammation, vascular injury and repair in rheumatoid arthritis. Ann Rheum Dis 2010;69:57-60.
  6. Distler JH, Beyer C, Schett G, Lüscher TF, Gay S, Distler O. Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 2009;60:3168-79.
  7. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, et al. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014;65:773-7.
  8. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64.
  9. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929-36.
  10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheuma